Wow, they seem to have jumped all over this very fast.

Just posting this Clinical Trial info. below as a follow up to the articles in a previous post which was...
HDC (Histidine Decarboxylase) gene

_____________

http://www.tsa-usa.org/aResearch/Saf...l_AZD5213.html

• Non-TSA Funded Study

Safety, Tolerability, Pharmacokinetic, and Efficacy of AZD5213 in Adolescents With Tourette's Disorder
Summit, NJ; Orange, CA; New York, NY; St. Petersburg, FL

http://clinicaltrials.gov/ct2/show/NCT01904773
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
This study is currently recruiting participants.

[Added note:
Sponsor:AstraZeneca]

_____________

http://www.prweb.com/releases/2014/03/prweb11637784.htm
March 05, 2014
- gives an explanation about how their drug targets histamine H3 receptor.
- dopamine regulation

_____________

I've just been doing some detective work and what do you know...

There's that T word again... Targacept

AstraZeneca quietly sweeps out some notable mid-stage drug programs
February 6, 2014 | By John Carroll
http://www.fiercebiotech.com/story/a...ams/2014-02-06

_____________

Targacept

http://neurotalk.psychcentral.com/post829509-71.html
Regarding Mecamylamine/Inversine etc.
TC-5214